Overview

Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients

Status:
Terminated
Trial end date:
2018-11-06
Target enrollment:
Participant gender:
Summary
This is a long-term open-label safety extension to the Phase 2a study of inhaled QCC374 in adult patients with PAH. This study provides the patients who completed the QCC374X2201 study with the option to continue receiving QCC374. The study will monitor the long-term safety, tolerability and efficacy of QCC374 in patients with PAH.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals